ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 941,64
0,00%
Dow Jones
44 882,13
0,38%
DAX
21 727,20
0,48%
Brent Oil
76,225
0,23%
Bitcoin
104 496,75
-0,23%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. PainReform Ltd (PRFX)

  7. PainReform Ltd (PRFX) Actualités

PRFX

PainReform (PRFX)

PainReform Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PRFX
DateHeureSourceTitreSymboleSociété
02/01/202522h15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRFXPainReform Ltd
02/01/202522h06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
27/12/202414h30GlobeNewswire Inc.PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110NASDAQ:PRFXPainReform Ltd
13/12/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRFXPainReform Ltd
12/12/202423h00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PRFXPainReform Ltd
06/12/202422h30Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:PRFXPainReform Ltd
20/11/202414h30GlobeNewswire Inc.PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical TrialNASDAQ:PRFXPainReform Ltd
07/11/202423h00GlobeNewswire Inc.PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementNASDAQ:PRFXPainReform Ltd
11/09/202414h30GlobeNewswire Inc.PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110NASDAQ:PRFXPainReform Ltd
10/09/202415h46GlobeNewswire Inc.PainReform Announces Exercise of Warrants for $1.58 Million Gross ProceedsNASDAQ:PRFXPainReform Ltd
28/08/202422h30Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:PRFXPainReform Ltd
27/08/202423h07Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PRFXPainReform Ltd
21/08/202414h30GlobeNewswire Inc.PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy ProceduresNASDAQ:PRFXPainReform Ltd
20/08/202414h30GlobeNewswire Inc.PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy StudyNASDAQ:PRFXPainReform Ltd
15/08/202414h00GlobeNewswire Inc.PainReform Provides Business Update for the Second Quarter of 2024NASDAQ:PRFXPainReform Ltd
12/08/202415h00GlobeNewswire Inc.PainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic EffectsNASDAQ:PRFXPainReform Ltd
07/08/202416h00GlobeNewswire Inc.PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher DosesNASDAQ:PRFXPainReform Ltd
05/08/202415h00GlobeNewswire Inc.PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110NASDAQ:PRFXPainReform Ltd
01/08/202414h30GlobeNewswire Inc.PainReform’s New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room TemperatureNASDAQ:PRFXPainReform Ltd
24/07/202414h30GlobeNewswire Inc.PainReform Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and TestingNASDAQ:PRFXPainReform Ltd
26/06/202414h00GlobeNewswire Inc.PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110NASDAQ:PRFXPainReform Ltd
31/05/202422h15GlobeNewswire Inc.PainReform Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:PRFXPainReform Ltd
15/05/202422h05GlobeNewswire Inc.PainReform Provides Business Update for the First Quarter of 2024NASDAQ:PRFXPainReform Ltd
08/05/202414h30GlobeNewswire Inc.PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.comNASDAQ:PRFXPainReform Ltd
18/04/202420h19GlobeNewswire Inc.PainReform Announces Closing of $4 Million Public OfferingNASDAQ:PRFXPainReform Ltd
16/04/202414h00GlobeNewswire Inc.PainReform Announces Pricing of $4 Million Public OfferingNASDAQ:PRFXPainReform Ltd
09/04/202415h00GlobeNewswire Inc.PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing ConditionsNASDAQ:PRFXPainReform Ltd
02/04/202414h30GlobeNewswire Inc.PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in BunionectomyNASDAQ:PRFXPainReform Ltd
01/03/202422h34Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:PRFXPainReform Ltd
01/03/202414h00GlobeNewswire Inc.PainReform Provides Year-End Business UpdateNASDAQ:PRFXPainReform Ltd
 Showing the most relevant articles for your search:NASDAQ:PRFX

Dernières Valeurs Consultées

BITMOT
814041
Eib Green Bond Tf 2,375%...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces